Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery of a B-Cell Lymphoma 6 Protein–Protein Interaction Inhibitor by a Biophysics-Driven Fragment-Based Approach

4 May 2017

Abstract excerpt

B-cell lymphoma 6 (BCL6) is a transcriptional factor that expresses in lymphocytes and regulates the differentiation and proliferation of lymphocytes. Therefore, BCL6 is a therapeutic target for autoimmune diseases and cancer treatment. This report presents the discovery of BCL6–corepressor interaction inhibitors by using a biophysics-driven fragment-based approach. Using the surface plasmon resonance (SPR)-based...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Lymphoma Diagnosis and Treatment
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28471657
DOI: 10.1021/acs.jmedchem.7b00313

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery of a B-Cell Lymphoma 6 Protein–Protein Interaction Inhibitor by a Biophysics-Driven Fragment-Based ApproachPMID 28471657Read ↗

Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and BeyondSemantic proximity Read ↗

Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphomaSemantic proximity Read ↗

BCL6 as a therapeutic target for lymphoma.Semantic proximity Read ↗

A regulatory SH2 domain-targeting protein binder effectively inhibits the activity of Bruton's tyrosine kinase and its drug-resistant variants.Semantic proximity Read ↗

Evolution of nanobodies specific for BCL11ASemantic proximity Read ↗

Designed peptide binders and nanobodies as PROTAC starting points for targeted degradation of PCNA and BCL6Semantic proximity Read ↗

Traversing through the Dynamic Protein–Protein Interaction Landscape and Conformational Plasticity of PD-1 for Small-Molecule DiscoverySemantic proximity Read ↗

Profiling protein–protein interactions to predict the efficacy of B-cell-lymphoma-2-homology-3 mimetics for acute myeloid leukaemiaSemantic proximity Read ↗

A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivoSemantic proximity Read ↗

Structural Details of BH3 Motifs and BH3-Mediated Interactions: an Updated PerspectiveSemantic proximity Read ↗

Structure-based redesign of the binding specificity of anti-apoptotic Bcl-x(L).Semantic proximity Read ↗

Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.